Advertisement

Topics

Latest Biotechnology, Pharmaceutical and Healthcare News - Page: 2

08:42 EST 19th February 2019 | BioPortfolio

Showing News Articles 26–50 of 430,000+

Tuesday 19th February 2019

BIOTONE Announces New Lab+Blends CBD Massage Oil

High Levels of CBD Promote Wellness and Pain Relief for Sprains, Strains and Sports Injuries BIOTONE has introduced Lab+Blends CBD Massage Oil Increased Relief & Recovery

Simon Moroney, CEO and Co-Founder of MorphoSys, Announces His Intention to Retire (news with additional features)

DGAP-News: MorphoSys AG / Key word(s): Personnel 19.02.2019 / 12:52 The issuer is solely responsible for the content of this announcement. Planegg/Munich, Germany, February 19, 2019 Simon Moroney, CEO and Co-Founder of MorphoSys, Announces His Intention to Retire Simon Moroney, CEO and co-founder of MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX & MDAX; NASDAQ: MOR), infor...

Medtronic Receives FDA Breakthrough Designation for Developing Personalized Closed Loop Insulin Pump System for Diabetes Management

DUBLIN - February 19, 2019 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA) for its Personalized Closed Loop (PCL) insulin pump system, currently in development. The PCL technology is designed to automate insulin delivery in a way that is real-time, per...

$ORPN Announces Sale of its Trehalose Clinical Development Programs to Seelos Therapeutics. Unconditional payment of $3.5M Contingent payment of up to additional $17M plus royalties https://globenewswire.com/news-release/2019/02/19/1734172/0/en/Bioblast-P

$ORPN Announces Sale of its Trehalose Clinical Development Programs to Seelos Therapeutics. Unconditional payment of $3.5M Contingent payment of up to additional $17M plus royalties https://globenewswire.com/news-release/2019/02/19/1734172/0/en/Bioblast-Pharma-Announces-Sale-of-its-Trehalose-Clinical-Development-Programs-to-Seelos-Therapeutics.html …

Medtronic Reports Third Quarter Financial Results

Revenue of $7.5 Billion Increased 2.4% Reported; Increased 4.4% Organic  GAAP Diluted EPS of $0.94; Non-GAAP Diluted EPS of $1.29 Operating Margin of 20.4% Increased 90 bps; Non-GAAP Operating Margin of 29.2% Increased 140 bps Cash Flow from Operations of $4.9 Billion in First Nine Months vs. $3.6 Billion in Prior Year; Free Cash Flow of $4.1 Billion in First N...

Dr. Richard Amato, Periodontist in Monroe, CT, Raises Awareness of Gum Disease and Diabetes Connection, Offers Laser Gum Therapy

Periodontist, Dr. Richard Amato, raises awareness of the relationship between diabetes and gum disease in Monroe, CT. Dr. Amato was recently featured on WTNH Channel 8 News discussing how minimally invasive LANAP® dentistry can effectively help patients manage gum disease. MONROE, Conn. (PRWEB) February 19, 2019 Experienced periodontist, Dr. Richard Amato of Advanced Periodontics and Dental ...

New App, Parqueo, Launches in Seattle to Solve City’s Parking Problem

An innovative new app for parking spot owners to rent out their privately-owned parking spots in Seattle launches in the iTunes and Google Play stores. SEATTLE (PRWEB) February 19, 2019 Parqueo, a mobile app that lets Seattle locals rent out their privately-owned parking spaces launches on the iTunes and Google Play. The app serves as a platform for parking space owners to market their unused spa...

$IMNP Files for Chapter 11 Protection

$IMNP Files for Chapter 11 Protection

NHS long term plan is just one part of the picture

In recognising that the NHS 10 year plan “seeks to contribute what is within its compass,” Chapman and Middleton explain why any plan constrained by organisational boundaries cannot be a...

We speak to Seqirus on its Flucelvax Tetra becoming the first cell-based, quadrivalent #influenza vaccine approved in Europe, and the rising threat of vaccine hesitancy http://bit.ly/2Sau4YY  #flu #pharmapic.twitter.com/ys35n9B8vd

We speak to Seqirus on its Flucelvax Tetra becoming the first cell-based, quadrivalent #influenza vaccine approved in Europe, and the rising threat of vaccine hesitancy http://bit.ly/2Sau4YY  #flu #pharma

CORRECTING and REPLACING NHI Announces Fourth Quarter 2018 Results

In the table titled "Condensed Statements of Income," the year ranges in the column headers should be 2018 and 2017, instead of 2019 and 2018. The corrected release reads: CORRECTING AND REPLACING NHI ANNOUNCES FOURTH QUARTER 2018 RESULTS National Health Investors, Inc. (NYSE:NHI) announced today its net income, ...

Ad hoc: Simon Moroney, CEO and Co-Founder of MorphoSys, Announces His Intention to Retire

MorphoSys AG / Key word(s): Personnel Ad hoc: Simon Moroney, CEO and Co-Founder of MorphoSys, Announces His Intention to Retire 19-Feb-2019 / 12:35 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Planegg/Munich,...

-Janssen's esketamine recommended by #FDA panel for #depression -Can #AI solve the drug development problem? Find out in our new feature -#FMD would not apply in case of no-deal #Brexit -Gilead's CAR-T therapy #Yescarta rejected for #NHS use in Scotland

-Janssen's esketamine recommended by #FDA panel for #depression -Can #AI solve the drug development problem? Find out in our new feature - #FMD would not apply in case of no-deal #Brexit -Gilead's CAR-T therapy

KnipBio Earns GRAS Green Light from FDA for Novel Aquafeed Protein

(Lowell, MA) February 18, 2019. KnipBio Inc. announced today it has received Generally Regarded As Safe (GRAS) designation from the US Food and Drug Administration (FDA) Center for Veterinary Medicine for its KnipBio Meal (KBM) aquafeed ingredient for salmonids and other finfish species. The designation was achieved after an extensive review of feed trial results by an […] The post KnipBio...

$ONCE Reports 2018 Financial Results and Recent Business Progress https://finance.yahoo.com/news/spark-therapeutics-reports-2018-financial-123000828.html …

$ONCE Reports 2018 Financial Results and Recent Business Progress https://finance.yahoo.com/news/spark-therapeutics-reports-2018-financial-123000828.html …

Human medicines European public assessment report (EPAR): Rubraca, rucaparib, Ovarian Neoplasms, Date of authorisation: 23/05/2018, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Rubraca, rucaparib, Ovarian Neoplasms, Date of authorisation: 23/05/2018, Revision: 2, Status: Authorised

Aerie Pharmaceuticals to Announce Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on Monday, February 25, 2019

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye announced today that its fourth quarter and full year 2018 financial results will be re...

MEDNAX Launches Private Offering of $200 Million of 6.250% Senior Notes Due 2027

MEDNAX, Inc. (NYSE: MD), announced today that it is proposing to issue $200 million aggregate amount of 6.250% senior notes due 2027 (the “Notes”) in a private offering that is exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”). The Notes will be issued as additional notes under an indenture, dated ...

$APTX Initiates Phase 2 Study to Evaluate Safety and Efficacy of NYX-783 in Patients with Post-Traumatic Stress Disorder https://finance.yahoo.com/news/aptinyx-initiates-phase-2-study-122700822.html …

$APTX Initiates Phase 2 Study to Evaluate Safety and Efficacy of NYX-783 in Patients with Post-Traumatic Stress Disorder https://finance.yahoo.com/news/aptinyx-initiates-phase-2-study-122700822.html …

Philippines' FDA halts sales of Sanofi's #dengue vaccine http://bit.ly/2ScHaF8  #pharmapic.twitter.com/kl28wPFScX

Philippines' FDA halts sales of Sanofi's #dengue vaccine http://bit.ly/2ScHaF8  #pharma pic.twitter.com/kl28wPFScX

$ICPT Ph3 #NASH hit on fibrosis, fails on NASH resolution 5% severe severe pruritus and 3% hepatobiliary events makes 25mg commercially unviable thoughpic.twitter.com/I8jwW8OgI2

$ICPT Ph3 #NASH hit on fibrosis, fails on NASH resolution 5% severe severe pruritus and 3% hepatobiliary events makes 25mg commercially unviable though pic.twitter.com/I8jwW8OgI2

CRISPR Therapeutics and StrideBio Expand Exclusive Development and Option Agreement $CRSP https://finance.yahoo.com/news/crispr-therapeutics-stridebio-expand-exclusive-120000518.html …

CRISPR Therapeutics and StrideBio Expand Exclusive Development and Option Agreement $CRSP https://finance.yahoo.com/news/crispr-therapeutics-stridebio-expand-exclusive-120000518.html …

$ICPT + 32% in pre market

$ICPT + 32% in pre market

Arix Bioscience announces Joe Anderson as new CEO

College of Optometrists in Vision Development & Neuro Optometric Rehabilitation Association Issue Joint Recommendation for Optometric Evaluation Following Brain Injury

Visual problems often overlooked during initial treatment of a brain injury; Left untreated, can have serious consequences The College of Optometrists in Vision Development (COVD) and the Neuro Optometric Rehabilitation AssociationTM (NORA), today, issued a joint call-to-action to all healthcare professionals to consider the need for medical and...


Advertisement
Quick Search
Advertisement
Advertisement

 

BioPortfolio's biotechnology, pharmaceutical, healthcare and medical device tracking service collates press releases, news articles and blogs from over 500 sources.  Continuous news is published on the BioPortfolio site, categorised into core topics and posted to our social media accounts - currently 127,000 followers (January 2019):